CA
EXAS

Cambridge Associates’s Exact Sciences EXAS Stock Holding History

Cambridge Associates’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-23,862
Closed -$1.86M – 45
2021
Q4 		$1.86M Buy
23,862
+11,931
+100% +$1.05M 0.07% 42
2021
Q3 		$1.13M Buy
+11,931
New +$1.26M 0.1% 41

Other funds holding EXAS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cambridge Associates's EXAS Position: Q1 2022 in Review

Cambridge Associates sold out of Exact Sciences (EXAS) in Q1 2022, closing a stake of 23,862 shares — an estimated $1.86M sold.

Cambridge Associates first reported a position in EXAS in Q3 2021 and held it in 2 quarters. The position peaked at $1.86M in Q4 2021. 559 funds tracked by Wall St. Rank hold EXAS as of Q1 2022.

  • Cambridge Associates reported no remaining Exact Sciences position as of Q1 2022 after selling out during the quarter.
  • Cambridge Associates sold 23,862 Exact Sciences shares in Q1 2022, an estimated $1.86M.
  • Cambridge Associates first reported a position in Exact Sciences in Q3 2021 and held it in 2 quarters.
  • Cambridge Associates's Exact Sciences position peaked at $1.86M in Q4 2021.
  • 559 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2022.

Based on Cambridge Associates's 13F filing for Q1 2022, filed 16 May 2022.